Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

Moderna to get desired result for final COVID-19 vaccine trials in 5 months

Chike Olisah by Chike Olisah
June 16, 2020
in Coronavirus
Moderna to get desired result for final covid-19 vaccine trials in 5 months
Share on FacebookShare on TwitterShare on Linkedin

As the race for a breakthrough in the discovery of vaccine by different drug manufacturers intensifies, American biotech firm, Moderna Inc, has given an idea of when they hope to get the desired result for the COVID-19 vaccine trial.

The Chief Executive Officer of Moderna Inc, Stephane Bancel, said that the efficacy data for its COVID-19 vaccine could be available by as soon as Thanksgiving, that is, by November if everything goes right.

RelatedPosts

FG says Nigeria gathering vaccine producers to develop technology in case of future outbreaks

You can now go to United States without COVID-19 tests

Moderna’s coronavirus vaccine is in second stage trials, with final stage trials expected to start by next month on 30,000 people.

According to Bloomberg, Stephane Bancel in an interview said, “We could have efficacy data by Thanksgiving. This is the best timeline. While the US Food and Drug Administration would decide what to do next, they might decide to give us emergency use approval for people at very high risk, while the agency more carefully reviews the data before granting approval for a broader population.”

READ MORE: Covid-19: US regulator revokes use of Hydroxychloroquine

He expressed cautious optimism that one or more of the vaccines in testing would work.

On the possibility that the coronavirus vaccine would prevent the disease but not completely stop COVID-19 infection as raised by some vaccine experts, Bancel said that the primary goal will be to prevent sickness, while Moderna’s big trial will measure whether the vaccine prevents infection.

According to him, “The number one priority is to make sure you get no disease, because of course people die from disease, not from infection.” 

He said although the vaccines will not be free, as businesses don’t work like that, they are working at making its price affordable.

It can be recalled that a recent report had suggested that Moderna COVID-19 vaccine test on mice shows that it may not increase the risk of more serious diseases and that may provide protection against the COVID-19 virus by shielding vital organs such as lungs and noses, without side effects.

Bancel disclosed that it took Moderna 63 days, that is 2 months, to go from the sequence of a virus to start the clinical trial by injecting a human, but when they did the vaccine for Severe Acute Respiratory Syndrome (SARS) it took about 20 months to go from a sequence of a virus to starting clinical trials.

 

Related

Tags: American biotech firmCovid-19 vaccineModerna IncModerna’s coronavirus vaccineStephane Bancel

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Hot forex
Cornerstone
Mega Millions
Polaris Bank
Eco Bank
Access Bank
Bankers Committee
First bank


FCMB
Ikeja Electrics




    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • Final countdown commences for Konga mid-year shopping festival
    • Bread bakers to embark on a two-week strike
    • Nigeria leads Rest of Africa in MultiChoice subscription revenue

    Follow us on social media:

    Recent News

    Final countdown commences for Konga mid-year shopping festival

    Final countdown commences for Konga mid-year shopping festival

    June 26, 2022
    Bread price hike looms as bakers association approves 30% increase

    Bread bakers to embark on a two-week strike

    June 26, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com